The stock price of Contineum Therapeutics Inc (NASDAQ: CTNM) has jumped by 21.04 compared to previous close of 3.66. Despite this, the company has seen a gain of 24.26% in its stock price over the last five trading days. businesswire.com reported 2025-05-15 that SAN DIEGO–(BUSINESS WIRE)–Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th at 8:30 a.m. ET. An audio webcast of the presentation can be accessed on the Investors section.
Is It Worth Investing in Contineum Therapeutics Inc (NASDAQ: CTNM) Right Now?
Moreover, the 36-month beta value for CTNM is 0.51. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CTNM is 13.50M and currently, short sellers hold a 4.50% of that float. On June 03, 2025, CTNM’s average trading volume was 80.23K shares.
CTNM’s Market Performance
The stock of Contineum Therapeutics Inc (CTNM) has seen a 24.26% increase in the past week, with a 11.59% rise in the past month, and a -32.78% fall in the past quarter. The volatility ratio for the week is 9.43%, and the volatility levels for the past 30 days are at 8.39% for CTNM. The simple moving average for the past 20 days is 15.63% for CTNM’s stock, with a -62.40% simple moving average for the past 200 days.
Analysts’ Opinion of CTNM
Many brokerage firms have already submitted their reports for CTNM stocks, with Robert W. Baird repeating the rating for CTNM by listing it as a “Outperform.” The predicted price for CTNM in the upcoming period, according to Robert W. Baird is $32 based on the research report published on October 22, 2024 of the previous year 2024.
Stifel, on the other hand, stated in their research note that they expect to see CTNM reach a price target of $29. The rating they have provided for CTNM stocks is “Buy” according to the report published on April 30th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to CTNM, setting the target price at $30 in the report published on April 30th of the previous year.
CTNM Trading at -6.95% from the 50-Day Moving Average
After a stumble in the market that brought CTNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.86% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CTNM starting from Lorrain Daniel S., who sale 1,010 shares at the price of $16.02 back on Nov 25 ’24. After this action, Lorrain Daniel S. now owns 168,562 shares of Contineum Therapeutics Inc, valued at $16,177 using the latest closing price.
Lorrain Daniel S., the Chief Scientific Officer of Contineum Therapeutics Inc, sale 6,190 shares at $16.38 during a trade that took place back on Nov 18 ’24, which means that Lorrain Daniel S. is holding 169,572 shares at $101,421 based on the most recent closing price.
Stock Fundamentals for CTNM
Current profitability levels for the company are sitting at:
- -244.11 for the present operating margin
- 0.25 for the gross margin
The net margin for Contineum Therapeutics Inc stands at -205.91. The total capital return value is set at -0.31. Equity return is now at value -91.32, with -30.97 for asset returns.
Based on Contineum Therapeutics Inc (CTNM), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -6.52.
Currently, EBITDA for the company is -42.0 million with net debt to EBITDA at 0.32. When we switch over and look at the enterprise to sales, we see a ratio of 405.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.47.
Conclusion
To wrap up, the performance of Contineum Therapeutics Inc (CTNM) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
